rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2004-10-12
|
pubmed:abstractText |
Hydroxyurea (HU) is known to increase gamma-globin chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still unclear. The aim of this study was to monitor treatment of a large cohort of patients with beta-thalassemia major in order to establish the response to HU and the associated elements.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1592-8721
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
89
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1172-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15477200-Adolescent,
pubmed-meshheading:15477200-Adult,
pubmed-meshheading:15477200-Alleles,
pubmed-meshheading:15477200-Blood Transfusion,
pubmed-meshheading:15477200-Child,
pubmed-meshheading:15477200-Combined Modality Therapy,
pubmed-meshheading:15477200-DNA Mutational Analysis,
pubmed-meshheading:15477200-Drug Resistance,
pubmed-meshheading:15477200-Female,
pubmed-meshheading:15477200-Fetal Hemoglobin,
pubmed-meshheading:15477200-Genetic Heterogeneity,
pubmed-meshheading:15477200-Globins,
pubmed-meshheading:15477200-Haplotypes,
pubmed-meshheading:15477200-Humans,
pubmed-meshheading:15477200-Hydroxyurea,
pubmed-meshheading:15477200-Iran,
pubmed-meshheading:15477200-Male,
pubmed-meshheading:15477200-Splenectomy,
pubmed-meshheading:15477200-Treatment Outcome,
pubmed-meshheading:15477200-beta-Thalassemia
|
pubmed:year |
2004
|
pubmed:articleTitle |
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
|
pubmed:affiliation |
Thalassemia Medical Center, Medical Faculty, Bandar Abbas University, Iran.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|